Comparative Pharmacology
Head-to-head clinical analysis: FAMOTIDINE CALCIUM CARBONATE AND MAGNESIUM HYDROXIDE versus XPHOZAH.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FAMOTIDINE CALCIUM CARBONATE AND MAGNESIUM HYDROXIDE versus XPHOZAH.
FAMOTIDINE, CALCIUM CARBONATE, AND MAGNESIUM HYDROXIDE vs XPHOZAH
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Famotidine is a competitive histamine H2-receptor antagonist that inhibits gastric acid secretion by blocking H2 receptors on parietal cells. Calcium carbonate and magnesium hydroxide act as antacids, neutralizing gastric acid via chemical neutralization.
XPHOZAH (tenapanor) is a sodium-hydrogen exchanger 3 (NHE3) inhibitor. It acts locally in the gastrointestinal tract to inhibit NHE3, reducing sodium and phosphate absorption, leading to decreased serum phosphate levels.
1 tablet (famotidine 10 mg, calcium carbonate 800 mg, magnesium hydroxide 165 mg) orally once or twice daily as needed for heartburn; maximum 2 tablets in 24 hours.
10 mg orally three times daily (TID) with or without food.
None Documented
None Documented
Famotidine: 2.5-3.5 hours (prolonged in renal impairment, up to 20 hours when CrCl <10 mL/min).
Terminal elimination half-life is approximately 14 days, supporting monthly subcutaneous dosing for sustained serum phosphate reduction.
Famotidine: renal (65-70% unchanged), biliary/fecal (30-35%). Calcium carbonate: feces (unabsorbed calcium), urine (absorbed). Magnesium hydroxide: feces (unabsorbed magnesium), urine (absorbed).
Primarily eliminated in feces (approximately 92%) as unchanged drug; renal excretion is negligible (<1%).
Category A/B
Category C
Antacid / Laxative
Laxative